Related Experiment Video
Updated: Aug 18, 2026
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?
E C Chinje1, A V Patterson, M P Saunders
1Experimental Oncology Group, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, UK.
Abstract:
The bioreductive drug tirapazamine (TPZ, SR 4233, WIN 59075) is a lead compound in a series of potent cytotoxins that selectively kill hypoxic rodent and human solid tumour cells in vitro and in vivo. Phases II and III trials have demonstrated its efficacy in combination with both fractionated radiotherapy and some chemotherapy. We have evaluated the generality of an enzyme-directed approach to TPZ toxicity by examining the importance of the one-electron reducing enzyme NADPH:cytochrome P450 reductase (P450R) in the metabolism and toxicity of this lead prodrug in a panel of seven human non-small-cell lung cancer cell lines. We relate our findings on TPZ sensitivity in these lung lines with our previously published results on TPZ sensitivity in six human breast cancer cell lines (Patterson et al (1995) Br J Cancer 72: 1144-1150) and with the sensitivity of all these cell types to eight unrelated cancer chemotherapeutic agents with diverse modes of action. Our results demonstrate that P450R plays a significant role in the activation of TPZ in this panel of lung lines, which is consistent with previous observations in a panel of breast cancer cell lines (Patterson et al (1995) Br J Cancer 72: 1144-1150; Patterson et al (1997) Br J Cancer 76: 1338-1347). However, in the lung lines it is likely that it is the inherent ability of these cells to respond to multiple forms of DNA damage, including that arising from P450R-dependent TPZ metabolism, that underlies the ultimate expression of toxicity.
Insights
The bioreductive drug tirapazamine (TPZ) effectively targets hypoxic tumor cells. Its activation relies on NADPH:cytochrome P450 reductase (P450R), crucial for TPZ
Area of Science:
- Pharmacology
- Oncology
- Biochemistry
Background:
- Tirapazamine (TPZ) is a bioreductive prodrug selectively targeting hypoxic tumor cells.
- TPZ has shown efficacy in combination therapies with radiotherapy and chemotherapy.
- The enzyme NADPH:cytochrome P450 reductase (P450R) is implicated in TPZ metabolism and toxicity.
Purpose of the Study:
- To evaluate the role of P450R in TPZ metabolism and toxicity across seven human non-small-cell lung cancer (NSCLC) cell lines.
- To compare TPZ sensitivity in NSCLC lines with previously studied breast cancer cell lines.
- To assess the relationship between TPZ sensitivity and response to other chemotherapeutic agents.
Main Methods:
- Assessed TPZ sensitivity in seven human NSCLC cell lines.
- Examined the role of P450R in TPZ activation and toxicity.
- Compared findings with existing data on breast cancer cell lines and other chemotherapeutics.
Main Results:
- P450R plays a significant role in TPZ activation in the studied NSCLC cell lines.
- TPZ sensitivity in NSCLC lines is consistent with observations in breast cancer cell lines.
- The ultimate toxicity of TPZ in lung cancer cells appears linked to their inherent DNA damage response mechanisms.
Conclusions:
- P450R is important for tirapazamine activation in non-small-cell lung cancer.
- Cellular DNA damage response pathways are critical for mediating TPZ-induced toxicity.
- Findings support the enzyme-directed approach for TPZ in cancer therapy.
